<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1538973079464292&amp;ev=PageView&amp;noscript=1">

All Blog Posts

A Day of Unity and Action in Washington, D.C.: Reflections from GLA's Vice Chair
December 4, 2024
GLA Vice Chair, Debbie Siciliano, reflects on a transformative day in Washington, D.C., uniting advocates, researchers, and leaders to confront the realities of Lyme disease and demand progress. As I ...
The Advantage of Public-Private Partnerships to Accelerate Progress for Patients
June 23, 2020
GLA’s CEO Scott Santarella shares his insight on how scientific advancements that benefit patients can be accelerated through public-private partnerships, as he witnessed during his previous work in c...
How the New "Maybe It's Lyme" Article Hurts Lyme Patients
July 26, 2019
Is this becoming a trend? Another opinion piece on Lyme disease that dismisses post-treatment and chronic Lyme disease. The author calls these debilitating stages of Lyme an “identity” for people rath...
GLA Letter to Assistant Secretary of Health Re: TBDWG
July 18, 2019
Below is text from the letter sent to the Assistant Secretary of Health at the U.S. Department of Health and Human Services regarding changes to the 2019 Tick-Borne Disease Working Group, by GLA Chair...
One Article Cannot Dismiss the Facts About Lyme Disease
July 3, 2019
Updated on July 9 to include link to GLA’s Letter to the Editor that was submitted, and accepted, by The New York Times.
Request for Information: Input on NIH Tick-borne Diseases Strategic Plan
March 14, 2019
Below is a letter from Global Lyme Alliance’s Chief Scientific Officer in response to the NIH’s request for information to their Tick-borne Diseases Strategic Plan
GLA POV: Identifying Vancomycin as an effective antibiotic for killing Borrelia burgdorferi
September 11, 2018
by Timothy Sellati, Ph.D., Chief Scientific Officer, GLA
REMEMBERING ONE OF OUR OWN
September 5, 2018
by Scott Santarella, CEO of Global Lyme Alliance
GLA POV: FDA Clears Quidel Lyme Disease Immunoassay for Sofia 2
March 22, 2018
by Timothy Sellati, Ph.D., Chief Scientific Officer, GLA
GLA Point of View on "First Multiplex Test for Tick-Borne Disease"
March 6, 2018
by Timothy Sellati, Ph.D., Chief Scientific Officer, GLA
GLA Point of View on New Lyme Disease Study
February 2, 2018
by Timothy Sellati, Ph.D., Chief Scientific Officer, GLA
GLA POV: Advances in Serodiagnostic Testing for Lyme Disease
December 22, 2017
by Timothy J. Sellati, Ph.D. Chief Scientific Officer Global Lyme Alliance
The Lyme Disease Divide
February 27, 2017
How to Make Sense of Conflicting Lyme Disease Facts
Lyme Disease Prevention Needs Co-Operation, Not Isolation
December 6, 2016
by Hannah Staab and Mayla Hsu, Ph.D., GLA Science Officer
Letter from CEO on Lyme Disease Research Initiatives
July 22, 2016
Global Lyme Alliance CEO Scott Santarella highlights key research initiatives in the 2015-2016 grants cycle.